ARTICLE | Clinical News
INS365: Began Phase III program
January 16, 2001 8:00 AM UTC
Inspire Pharmaceuticals Inc. (ISPH), Durham, N.C. Product: INS365 Ophthalmic solution Business: Ophthalmic Therapeutic category: Receptor agonist Target: P2Y2 receptors Description: Small molecule P2...